ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Darolutamide 300 mg
DRUG: Placebo
DRUG: Androgen deprivation therapy

Sponsor

UNICANCER

Collaborators

[object Object]